Here’s a quick rundown of recent news from major pharmaceutical companies that you might have missed. Amylyx Pharmaceuticals announced that a mid-stage clinical trial for its well-known drug, AMX0035, failed to meet its main goals. The study focused on treating a rare neurological condition called progressive supranuclear palsy. As a result, the company stopped the trial and a related extension study. However, Amylyx plans to continue developing AMX0035 for another rare disorder, Wolfram syndrome. The company’s top priority remains a late-stage study of a blood sugar medication it acquired last year. AMX0035 was previously approved in the U.S. for ALS but was pulled from the market in 2024, leaving Amylyx without its main source of income. The company expects its current funds to last through the end of next year. Sanofi has appointed Marcia Kayath, a pharmaceutical industry expert, as its new chief medical officer. Kayath previously led medical affairs at BioMarin Pharmaceuticals and has also worked at Novartis, Eli Lilly, and Pfizer. She will start her role on September 2 and will oversee Sanofi’s medical and patient safety teams. Novartis is teaming up with BioArctic, a Swedish company that developed the Alzheimer’s drug Leqembi, to create a new treatment for an undisclosed neurodegenerative disease. Novartis will pay BioArctic $30 million upfront, with the potential for up to $772 million in future payments if the collaboration succeeds. The companies will explore using a Novartis antibody with BioArctic’s technology designed to improve drug delivery to the brain. Genentech, a Roche subsidiary, recently began construction on its first East Coast manufacturing facility in North Carolina. The 700,000-square-foot site will produce cardiometabolic medicines, including treatments for obesity. The facility is expected to open in 2029 and will employ around 400 workers. Roche has committed to investing $50 billion in U.S. manufacturing over the next five years, partly in response to potential tariffs on pharmaceutical goods. Eisai, the Japanese company behind the Alzheimer’s drug Leqembi, started selling the medication in Europe this week. Leqembi launched in Austria on August 25 and will be available in Germany on September 1. European regulators approved the drug in April after a lengthy review, opening up a major revenue opportunity for Eisai and its partner Biogen. Analysts estimate that Leqembi could eventually generate up to $8.3 billion in annual sales, with 20% coming from Europe.